Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2020-05-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于董事长辞职的公告
Board/Management Information Classification · 100% confidence The document is a public announcement regarding the resignation of the company's chairman and other related positions. It includes details about the resignation date, reasons, and confirmation that the resignation does not affect the board's legal composition. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-05-22 Chinese
2019年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2019 Annual General Meeting (AGM) of Jiangsu Sihuan Bio Co., Ltd. It details the legality and validity of the AGM's convening, the qualifications of the convener and attendees, the voting procedures, and the voting results. The document references the 2019 AGM specifically and discusses the meeting process and resolutions passed. It does not contain the actual annual report or financial statements but rather a legal opinion on the AGM proceedings and results. Given the content focuses on the AGM and the legal opinion related to it, this fits the category of AGM Information (AGM-R). The document length is relatively short (3055 characters), and it is not an announcement of a report but a legal opinion letter on the AGM itself.
2020-05-15 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2019 Annual General Meeting (AGM) of 江苏四环生物股份有限公司. It details the voting results on various proposals including the 2019 annual report, financial statements, profit distribution plan, remuneration, and appointment of auditors. The document includes meeting details, attendance, voting procedures, and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves, but rather the official voting results and decisions made at the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3539 characters, which is consistent with an announcement rather than a full report. Confidence is high due to clear references to voting results and meeting resolutions.
2020-05-15 Chinese
关于有关当事人收到结案通知书的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the receipt of a case closure notice from the China Securities Regulatory Commission (CSRC). It details the investigation and administrative penalty notice previously received and now the case has been closed with no violations found for certain individuals. The document is short (551 characters) and serves as a regulatory update on legal proceedings related to the company, not a full audit report or annual report. It fits the category of Legal Proceedings Report (LTR) as it provides an update on regulatory investigation and case closure.
2020-05-12 Chinese
第八届监事会第十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resolution of the 17th meeting of the 8th Supervisory Board of Jiangsu Sihuan Bio. It includes the election of a new chairman of the Supervisory Board and confirms the legality and validity of the meeting. There are no financial statements, no detailed management discussion, no audit information, or other report content. The document is an official announcement of a board/management change, specifically the election of a new chairman of the Supervisory Board, which falls under Board/Management Information (MANG). The document length is short and focused on management changes, not a report or financial data.
2020-05-06 Chinese
2020年第一次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the convening, procedures, attendance, voting, and results of the 2020 first extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It reviews compliance with company law, securities law, and stock exchange rules. The document does not contain financial statements or financial performance data but focuses on the legal aspects of the shareholders' meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not an annual report, earnings release, or proxy solicitation. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 2771 characters, which is relatively short and focused on legal opinion rather than financial data or report publication announcement.
2020-05-06 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.